Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]

Draft guidance

Draft guidance (downloadable version) (PDF 226 KB)

Draft guidance (online commenting)

Committee papers (PDF 7.8 MB)

Public committee slides (PDF 760 KB)

Equality impact assessment (scoping) (PDF 144 KB)

Final scope (PDF 187 KB)

Draft scope and provisional stakeholder list comments table (post-referral) (PDF 229 KB)

Draft matrix post referral (PDF 195 KB)